SHANGHAI, Jan. 13, 2021 /PRNewswire/ -- Zhongchao Inc.
(NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare
services company offering patient management, online healthcare
information, professional training and educational services, today
announced that it co-sponsored the National Annual Conference
for Standardized Liver Cancer Diagnosis and Treatment (the "Annual
Conference") with China Association of Health Promotion and
Education and Chinese Society of Liver Cancer.
In 2020, Zhongchao worked with medical associations and
experts to jointly carry out a multi-year online education project
on the diagnosis and treatment of primary liver cancer. This
project aims to promote and implement the Guidelines for Diagnosis
and Treatment of Primary Liver Cancer in China (2019 Edition) (the "Guidelines")
published by the National Health Commission of the People's Republic of China. Based on the
professional interpretation and through its online platform,
Zhongchao facilitated training and implementation of the Guidelines
in over 200 cities for more than half a million medical
professionals. The Annual Conference provided a timely platform for
us to review last year's trainings on the standardized liver cancer
diagnosis and treatment. Participants of the Annual Conference
boasted seven fellows of Chinese Academy of Sciences, two renowned
professors and five executive chairmen from the editorial board of
the Guidelines. They led and joined discussions about clinical
experience and benefits of the Guidelines, and ways to improve and
update the Guidelines.
Jia Fan, Chinese Academy of
Sciences Fellow, President of Zhongshan Hospital at Fudan
University, and General Supervisor of the Guidelines, stated in the
Annual Conference, "prolonging patients' life is the most pressing
issue in the field of liver cancer treatment in China. We draft and continuously update the
Guidelines based on research developments and lead doctors'
clinical practice. We collect practitioners' feedback on clinical
application, such as the actual effects of standardized diagnosis
and treatment of liver cancer patients, to ensure that the
Guidelines are adjusted and updated to adapt to China's evolving environment and doctors and
patients' real needs."
Weiguang Yang, Chairman and Chief
Executive Officer of Zhongchao, commented, "Every update of the
Guidelines reflects experience and data contributed by many medical
experts and clinical practitioners. The Guidelines will undergo a
new round of update in 2021 to meet the demand of rapid
developments in liver cancer diagnosis and treatment in recent
years. Zhongchao's job is to utilize its innovative training
platform to promote effective and efficient implementation of the
Guidelines. We will continue working with medical associations
to help clinical practitioners, especially the primary doctors,
understand the Guidelines quickly and accurately. Their better and
more accurate application of the Guidelines in clinical practice
will eventually benefit the patients."
About Zhongchao Inc.
Incorporated in 2012 with headquarter offices
in Shanghai and Beijing, China, Zhongchao
Inc. is an online provider of healthcare information,
professional training and educational services to healthcare
professionals under its "MDMOOC" platform (www.mdmooc.org) and to
the public under its "Sunshine Health Forums" platform
(www.ygjkclass.com) in China. The Company also offers patient
management services under its "Zhongxun" platform
(www.zhongxun.online). More information about the Company can be
found at its investor relations website
at http://izcmd.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may, "will, "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Forward-looking statements are not guarantees of
future performance and involve risks and uncertainties that may
cause the actual results to differ materially from the Company's
expectations discussed in the forward-looking statements. These
statements are subject to uncertainties and risks including, but
not limited to, the following: the Company's goals and
strategies; the Company's future business development; product and
service demand and acceptance; changes in technology; economic
conditions; the growth of the professional training and educational
services market in China and the other international
markets the Company plans to serve; reputation and brand; the
impact of competition and pricing; government regulations;
fluctuations in general economic and business conditions
in China and the international markets the Company plans
to serve and assumptions underlying or related to any of the
foregoing and other risks contained in reports filed by the Company
with the SEC, the length and severity of the recent
coronavirus outbreak, including its impacts across our business and
operations. For these reasons, among others, investors are
cautioned not to place undue reliance upon any forward-looking
statements in this press release. Additional factors are discussed
in the Company's filings with the SEC, which are available for
review at www.sec.gov. The Company undertakes no obligation to
publicly revise these forward–looking statements to reflect events
or circumstances that arise after the date hereof.
For more information, please contact:
At the Company: Pei Xu, CFO
Email: xupei@mdmooc.org
Phone: +86 21-3220-5987
Investor Relations: Sherry Zheng
Weitian Group LLC
Email: shunyu.zheng@weitian-ir.com
Phone: +1 718-213-7386
View original
content:http://www.prnewswire.com/news-releases/zhongchao-inc-promotes-standardized-liver-cancer-diagnosis-and-treatment-with-medical-associations-and-experts-301207065.html
SOURCE Zhongchao Inc.